01

JAAD Pilot Pits Mometasone Against Crisaborole and Tofacitinib

JAAD's November 2026 issue carries a randomized assessor-blinded pilot comparing mometasone 0.1%, crisaborole 2% and tofacitinib 2% ointments in mild to moderate atopic dermatitis.